U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13N3O5.ClH
Molecular Weight 279.678
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYTARABINE HYDROCHLORIDE

SMILES

Cl.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

InChIKey=KCURWTAZOZXKSJ-JBMRGDGGSA-N
InChI=1S/C9H13N3O5.ClH/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8;/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16);1H/t4-,6-,7+,8-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C9H13N3O5
Molecular Weight 243.2166
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Curator's Comment: Description was created using several sources including: http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28680 http://www.tandfonline.com/doi/abs/10.1517/17425247.2010.527330

Cytarabine is a pyrimidine nucleoside analog. Cytarabine or cytosine arabinoside (Cytosar-U or Depocyt) is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It also has antiviral and immunosuppressant properties. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It is a cell cycle phase-specific, affecting cells only during the S phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been explored extensively to enhance the half-life, stability and delivery of cytarabine. Alternative, delivery systems of cytarabine have emerged for the treatment of different cancers. The liposomal-cytarabine formulation has been approved for the treatment of lymphomatous meningitis.

CNS Activity

Originator

Curator's Comment: Cytarabine was first synthesized in 1959 by Richard Walwick, Walden Roberts, and Charles Dekker at the University of California, Berkeley. It was approved by the United States Food and Drug Administration in June 1969, and was initially marketed in the U.S. by Upjohn under the trade name Cytosar-U and is at present manufactured by Pfizer, Sicor Pharmaceuticals and Teva. CYTOSAR (cytarabine injection) was developed in September 1994 Dana-­Farber Cancer Institute and is manufactured by Pfizer and Perrigo. DEPOCYT - (cytarabine injection, lipid complex) manufactured by Manufactured by: Pacira Pharmaceuticals Inc., distributed by Sigma-Tau Pharmaceutical, Inc. is an intrathecal cancer chemotherapeutic agent approved by FDA is used for the treatment of lymphomatous meningitis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Primary
CYTARABINE

Approved Use

Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia.

Launch Date

1969
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
62.2 μg/mL
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1900 μg × h/mL
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
40.4 h
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
80 h
50 mg single, intrathecal
dose: 50 mg
route of administration: Intrathecal
experiment type: SINGLE
co-administered:
CYTARABINE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.363, 366
Disc. AE: Cerebellar disorder NOS, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Cerebellar disorder NOS (grade 4, 66.7%)
Diarrhea (grade 3, 66.7%)
Sources: Page: p.363, 366
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.2578
Disc. AE: Cerebellar disorder NOS, Cerebellar disorder NOS...
AEs leading to
discontinuation/dose reduction:
Cerebellar disorder NOS (grade 4, 33.3%)
Cerebellar disorder NOS (grade 5, 16.7%)
Sources: Page: p.2578
3 g/m2 2 times / day multiple, intravenous
MTD
Dose: 3 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 3 g/m2, 2 times / day
Sources: Page: p.366
unhealthy, 16-76
n = 27
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 27
Sources: Page: p.366
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Disc. AE: Bone marrow depression, Leukopenia...
AEs leading to
discontinuation/dose reduction:
Bone marrow depression
Leukopenia
Thrombocytopenia
Anemia
Nausea
Vomiting
Diarrhea
Abdominal pain
Oral ulceration
Hepatic dysfunction NOS
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Diarrhea grade 3, 66.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.363, 366
Cerebellar disorder NOS grade 4, 66.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.363, 366
Cerebellar disorder NOS grade 4, 33.3%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.2578
Cerebellar disorder NOS grade 5, 16.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.2578
Abdominal pain Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Anemia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Bone marrow depression Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Diarrhea Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Hepatic dysfunction NOS Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Leukopenia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Nausea Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Oral ulceration Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Thrombocytopenia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Vomiting Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 6.6 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases.
1976 Nov
Ocular toxicology.
1994 Dec
Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment.
1998 Jul
Protection by short-chain fatty acids against 1-beta-D-arabinofuranosylcytosine-induced intestinal lesions in germfree mice.
1999 Apr
Involvement of hydrogen peroxide and hydroxyl radical in chemically induced apoptosis of HL-60 cells.
1999 Jun 15
[Topotecan: a new field of use].
1999 Nov-Dec
Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia.
1999 Sep
Pseudotumor cerebri induced by all-trans-retinoic acid in a child treated for acute promyelocytic leukemia.
2000 Apr
Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1.
2000 Jan-Feb
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
2000 Jul
Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis.
2000 Jul 1
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
2000 Mar
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
2000 May
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
2000 May 1
Heterotopia in microcephaly induced by cytosine arabinoside: hippocampus in the neocortex.
2000 Oct
Treatment for primary CNS lymphoma: the next step.
2000 Sep
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.
2001 Apr
The neuron-glia signal beta-neuregulin promotes Schwann cell motility via the MAPK pathway.
2001 Apr 1
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
2001 Apr 1
Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents.
2001 Apr 1
The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.
2001 Apr 15
Parotid mucoepidermoid carcinoma following chemotherapy for childhood acute lymphoblastic leukemia.
2001 Apr-May
Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.
2001 Feb
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.
2001 Feb
Bilateral breast relapse in acute myelogenous leukemia.
2001 Feb
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
2001 Feb
Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect.
2001 Feb 15
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
2001 Feb 15
Topoisomerase II inhibitor induced leukemia in a patient with AIDS.
2001 Feb 16
Characterization of DNA fragmentation events caused by genotoxic and non-genotoxic agents.
2001 Feb 20
The biology and treatment of chronic myelogenous leukemia.
2001 Jan
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
2001 Jan
De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy.
2001 Jan
Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis.
2001 Jan
Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
2001 Jan 1
Bcl-X(L)-caspase-9 interactions in the developing nervous system: evidence for multiple death pathways.
2001 Jan 1
Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance.
2001 Jan 1
Porcine Choroid plexus epithelial cells in culture: regulation of barrier properties and transport processes.
2001 Jan 1
Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes.
2001 Jan 15
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
2001 Jan 3
Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia.
2001 Jan 5
Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs.
2001 Jan 5
The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study.
2001 Jan-Feb
Therapy of acute myeloid leukemia.
2001 Jan-Feb
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
2001 Mar
Neutrophilic eccrine hidradenitis in two neutropaenic patients.
2001 Mar
[All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].
2001 Mar
Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.
2001 Mar
Patents

Sample Use Guides

Induction therapy: DepoCyt (cytarabine liposome injection), 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 2 doses (weeks 1 and 3). Consolidation therapy: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13. Maintenance: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29).
Route of Administration: Intratracheal
In Vitro Use Guide
Curator's Comment: The effect of Ara-C (0.1 μM) treatment on HUVEC proliferation alone or in drug combinations compared to drug-free control cultures. Results are expressed as mean percentage ± SEM from three independent experiments (six replicates per condition) relative to corresponding untreated control cultures.
Human umbilical vein endothelial cells (HUVECs) and human osteosarcoma cell line (Cal72) were incubated with various concentrations of Cytarabine (Ara-C) (0.01–20 μM) for 3 days
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:12:42 GMT 2023
Edited
by admin
on Fri Dec 15 15:12:42 GMT 2023
Record UNII
33K3DB6591
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTARABINE HYDROCHLORIDE
USAN   WHO-DD  
USAN  
Official Name English
2(1H)-PYRIMIDINONE, 4-AMINO-1-.BETA.-D-ARABINOFURANOSYL-, MONOHYDROCHLORIDE
Common Name English
U-19920A
Code English
Cytarabine hydrochloride [WHO-DD]
Common Name English
CYTARABINE HYDROCHLORIDE [USAN]
Common Name English
1-.BETA.-D-ARABINOFURANOSYLCYTOSINE MONOHYDROCHLORIDE
Common Name English
CYTARABINE HCL
Common Name English
CYTOSINE ARABINOSIDE HYDROCHLORIDE
Common Name English
NSC-63878
Code English
Classification Tree Code System Code
NCI_THESAURUS C1557
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID5024891
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
ChEMBL
CHEMBL803
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
CAS
69-74-9
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
PUBCHEM
6252
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
EVMPD
SUB13523MIG
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
SMS_ID
100000092040
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
DRUG BANK
DBSALT002381
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
NCI_THESAURUS
C71603
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
FDA UNII
33K3DB6591
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
NSC
63878
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-713-9
Created by admin on Fri Dec 15 15:12:42 GMT 2023 , Edited by admin on Fri Dec 15 15:12:42 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY